Sanofi Pasteur Receives FDA Warning Letter

Article

On July 22, 2010, Sanofi Pasteur (Lyon, France) received a warning letter from the US Food and Drug Administration, citing deviations from current good manufacturing practices (cGMPs) in the manufacture of certain biological products and bulk drug substances, including Imovax Rabies, Imogam Rabies, Ipol, Act HIB, and Typhim Vi.

On July 22, 2010, Sanofi Pasteur (Lyon, France) received a warning letter from the US Food and Drug Administration, citing deviations from current good manufacturing practices (cGMPs) in the manufacture of certain biological products and bulk drug substances, including Imovax Rabies, Imogam Rabies, Ipol, Act HIB, and Typhim Vi.

The letter describes deviations that occurred during FDA inspections that took place between March 15 and April 2, 2010 at the company’s manufacturing site at Marcy l’Etoile, France.

Key cGMP deviations that were noted were the failure to report batch discrepancies and biological product deviations, and the failure to inform the FDA of changes in production processes.

Additionally, the letter noted manufacturing deviations including the failure to follow standard operating procedures to prevent microbial contamination.

The letter stated that the company’s responses dated April 21, May 17, and June 11, which addressed the inspectional observances on the 483 Form issued after the inspection was completed, have been acknowledged.

The entire letter can be found on the FDA’s web site.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagan, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.